Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2008 1
2009 2
2010 6
2011 8
2012 4
2013 5
2014 3
2015 8
2016 10
2017 5
2018 7
2019 7
2020 9
2021 12
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy.
Kizina K, Akkaya Y, Jokisch D, Stolte B, Totzeck A, Munoz-Rosales J, Thimm A, Bolz S, Brakemeier S, Pul R, Aslan D, Hackert J, Kleinschnitz C, Hagenacker T. Kizina K, et al. Among authors: pul r. Brain Sci. 2021 Sep 9;11(9):1184. doi: 10.3390/brainsci11091184. Brain Sci. 2021. PMID: 34573206 Free PMC article.
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
Rolfes L, Pfeuffer S, Hackert J, Pawlitzki M, Ruck T, Sondermann W, Korsen M, Wiendl H, Meuth SG, Kleinschnitz C, Pul R. Rolfes L, et al. Among authors: pul r. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 9;8(3):e990. doi: 10.1212/NXI.0000000000000990. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33837059 Free PMC article.
Antibody-based therapy in Alzheimer's disease.
Pul R, Dodel R, Stangel M. Pul R, et al. Expert Opin Biol Ther. 2011 Mar;11(3):343-57. doi: 10.1517/14712598.2011.552884. Epub 2011 Jan 25. Expert Opin Biol Ther. 2011. PMID: 21261567 Review.
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K, Schuh H, Pfister F, Krämer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gäckler A, Hagenacker T, Kribben A, Meuth SG, Kleinschnitz C, Pul R. Schönfelder K, et al. Among authors: pul r. Mult Scler. 2021 Oct;27(12):1960-1964. doi: 10.1177/13524585211022719. Epub 2021 Jun 24. Mult Scler. 2021. PMID: 34165361 Free PMC article.
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Rolfes L, et al. Among authors: pul r. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.
NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
Uphaus T, Steffen F, Muthuraman M, Ripfel N, Fleischer V, Groppa S, Ruck T, Meuth SG, Pul R, Kleinschnitz C, Ellwardt E, Loos J, Engel S, Zipp F, Bittner S. Uphaus T, et al. Among authors: pul r. EBioMedicine. 2021 Oct;72:103590. doi: 10.1016/j.ebiom.2021.103590. Epub 2021 Sep 24. EBioMedicine. 2021. PMID: 34571362 Free PMC article.
80 results